Braftovi Europska Unija - hrvatski - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastična sredstva - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Kisplyx Europska Unija - hrvatski - EMA (European Medicines Agency)

kisplyx

eisai gmbh - lenvatinib mesilat - karcinom, stanice bubrega - antineoplastična sredstva - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

LEMODDEPO 40 mg/1 mL suspenzija za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lemoddepo 40 mg/1 ml suspenzija za injekciju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - metilprednizolon - suspenzija za injekciju - 40 mg/1 ml - 1 ml suspenzije za injekciju sadrži: 40 mg metilprednizolon acetat